Base de dados : MEDLINE
Pesquisa : E05.916.270 [Categoria DeCS]
Referências encontradas : 17045 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1705 ir para página                         

  1 / 17045 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450249
[Au] Autor:Kurt A; Toker OS; Tornuk F
[Ad] Endereço:Department of Food Engineering, Engineering Faculty, Ondokuz Mayis University, 55139, Samsun, Turkey; Department of Food Engineering, Engineering and Architecture Faculty, Bitlis Eren University, 13000 Bitlis, Turkey. Electronic address: abdullahkurt48@gmail.com.
[Ti] Título:Effect of xanthan and locust bean gum synergistic interaction on characteristics of biodegradable edible film.
[So] Source:Int J Biol Macromol;102:1035-1044, 2017 Sep.
[Is] ISSN:1879-0003
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The present study was aimed to use different combinations of xanthan (XG) and locust bean gum (LBG) in the biodegradable edible film preparation by benefitting from their synergistic interactions for the first time. Concentrations of LBG, XG and glycerol of the optimized film sample were found to be 89.6%, 10.4% and 20%, respectively. At the optimum point the WVP, TS, E% and EM values of film were found 0.22gmmh m kPa, 86.97MPa, 33.34% and 177.25MPa, respectively. The optimized film was characterized for its physical, thermal and structural behavior. The scanning electron microscopy (SEM), X-ray diffraction (XRD), differential scanning calorimetry (DSC) and fourier transform infrared spectroscopy (FTIR) analyses exhibited miscibility and presence of interaction between polymers. In conclusion, XG and LBG interaction was used successfully to get biodegradable films and coatings with improved characteristics.
[Mh] Termos MeSH primário: Materiais Biocompatíveis/química
Galactanos/química
Mananas/química
Gomas Vegetais/química
Polissacarídeos Bacterianos/química
Embalagem de Produtos
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/metabolismo
Composição de Medicamentos
Glicerol/química
Fenômenos Mecânicos
Permeabilidade
Reologia
Vapor
Temperatura Ambiente
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Galactans); 0 (Mannans); 0 (Plant Gums); 0 (Polysaccharides, Bacterial); 0 (Steam); PDC6A3C0OX (Glycerol); TTV12P4NEE (xanthan gum); V4716MY704 (locust bean gum)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  2 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441913
[Ti] Título:Stimulation of bone regeneration with pigment epithelium-derived factor microparticles: evidence and .
[So] Source:Pharmazie;71(7):382-389, 2016 Jul 07.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The occurrence of bone defects can be due to a variety of factors not limited to bone fractures and tumours. Most diseased bone is removed and the patient fitted with prosthetics, prior to use of certain factors such as bone morphogenetic proteins (BMPs) to aid healing. Recently, the protein pigment epithelium-derived factor (PEDF) and the polysaccharide chitosan have been found to have promising effects on the regeneration of bone, with the major advantage of these agents being their safety to date. A study was performed to determine whether the combination of both chitosan and PEDF would enhance greater bone regeneration effects. Post-formulation, in silico tests (particle sizing and surface charge determination) were followed by several cell-based assays (microparticle cellular uptake, cytotoxicity, mitochondrial abundance, bone mineral formation, colony formation in matrigel, and colony formation in collagen I matrix), and finally in vivo testing where microparticles were injected periosteally in the hindlimb. Collectively, these findings support the idea that PEDF microencapsulated within chitosan promotes bone regeneration, and has potential for bone trauma management. Future studies will examine the ability of this promising bone regeneration microparticle to heal bone in disease states such as fracture and tumour-mediated osteolysis.
[Mh] Termos MeSH primário: Regeneração Óssea/efeitos dos fármacos
Proteínas do Olho/farmacologia
Fatores de Crescimento Neural/farmacologia
Serpinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Densidade Óssea/efeitos dos fármacos
Cápsulas
Sobrevivência Celular/efeitos dos fármacos
Quitosana/farmacologia
Colágeno Tipo I/farmacologia
Ensaio de Unidades Formadoras de Colônias
Simulação por Computador
Composição de Medicamentos
Proteínas do Olho/administração & dosagem
Proteínas do Olho/metabolismo
Membro Posterior
Seres Humanos
Injeções
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Mitocôndrias/efeitos dos fármacos
Fatores de Crescimento Neural/administração & dosagem
Fatores de Crescimento Neural/metabolismo
Tamanho da Partícula
Serpinas/administração & dosagem
Serpinas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Capsules); 0 (Collagen Type I); 0 (Eye Proteins); 0 (Nerve Growth Factors); 0 (Serpins); 0 (pigment epithelium-derived factor); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6010


  3 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386430
[Au] Autor:Hanawa T; Kawano Y; Satoh M
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Tokyo University of Science.
[Ti] Título:[Development of "Patient Friendly Formulations" to Counter the Side Effects of Cancer Chemotherapy].
[So] Source:Yakugaku Zasshi;138(2):169-175, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: Anticancer drug-induced stomatitis develops in 30% to 40% of cancer patients undergoing chemotherapy. However, medications for this condition are not commercially available in Japan. The "hospital formulation" is a customized medicine which hospital pharmacists prepare when doctors cannot carry out the medical therapy most suitable for a patient using commercial medicines. However, as the duties of pharmacists increase, use of the "hospital fomulation" decreases. Therefore, development of "hospital fomulations" based on individual evidence has a limit. Irsogladine maleate (IM) is a drug with gastric mucosal protective properties. IM increases intracellular cAMP levels in the gastric mucosa and activates communication between cells. It has been reported that the oral administration of IM reduces the incidence of 5-FU-based chemotherapy-induced stomatitis. However, there have been no reports on the effect of the direct use of IM in treating stomatitis. Therefore, we studied the development of an IM oral spray for stomatitis treatment, and obtained evidence of a direct effect in an animal experiment using a stomatitis model. Next, rebamipide mouthwash was administered to patients who had stomatitis caused by cancer chemotherapy. The total scores were classified into Grades 0 to 4 and evaluated as a stomatitis evaluation score (SES). When comparing SES and changes in the stomatitis area in patients, gradual reductions in the extent of stomatitis were observed, even during the period when SES did not change. Having patients fill in an observation chart was effective for grasping changes in symptoms in outpatients.
[Mh] Termos MeSH primário: Alanina/análogos & derivados
Antineoplásicos/efeitos adversos
Composição de Medicamentos
Quinolonas/administração & dosagem
Estomatite/induzido quimicamente
Estomatite/tratamento farmacológico
Triazinas/administração & dosagem
Triazinas/farmacologia
[Mh] Termos MeSH secundário: Administração Oral
Alanina/administração & dosagem
Animais
Comunicação Celular/efeitos dos fármacos
AMP Cíclico/metabolismo
Modelos Animais de Doenças
Medicina Baseada em Evidências
Mucosa Gástrica/citologia
Mucosa Gástrica/metabolismo
Seres Humanos
Antissépticos Bucais
Estomatite/prevenção & controle
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Mouthwashes); 0 (Quinolones); 0 (Triazines); E0399OZS9N (Cyclic AMP); LR583V32ZR (rebamipide); OF5P57N2ZX (Alanine); QBX79NZC1D (irsogladine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00174-2


  4 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441998
[Au] Autor:Saab M; Issa M; Samy W; El-Maradny H
[Ti] Título:Alternative approaches in formulating floating hollow tablets sublimation technique; a platform tailored drug release profile.
[So] Source:Pharmazie;71(12):701-708, 2016 Dec 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to formulate floating hollow tablets of salbutamol sulphate with a platform tailored drug release profile to attain a controllable drug release. Eight formulations (F1-F8) were prepared using sublimation technique. L-menthol was directly compressed as sublimable core followed by compression coating of hydroxypropylmethyl cellulose (HPMC-K15M) or polyethylene oxide (PEO-WSR301) as release retarding polymer coat. Tablets were then subjected to heat to allow sublimation of the core. The effect of polymer type and that of different drug coat/core distribution on swelling and drug release profile was studied. FTIR and DSC revealed the absence of any drug-excipients interaction. Tablets showed a hollow morphology, resulting in low density tablets that floated for over 24 hours without lag time. Moreover, different drug coat/core distribution resulted in controllable release profiles. Based on these results, an optimum drug release behavior was recorded for HPMC-based hollow tablets consisting of 2:1 drug coat/core distribution ratio (F4), revealing a zero order drug release for over 14 hours. Furthermore, F4 showed no changes in drug content, floating properties and drug release profile upon exposure to accelerated stability conditions.
[Mh] Termos MeSH primário: Preparações de Ação Retardada/química
Comprimidos/química
[Mh] Termos MeSH secundário: Varredura Diferencial de Calorimetria
Química Farmacêutica
Composição de Medicamentos
Liberação Controlada de Fármacos
Estabilidade de Medicamentos
Excipientes
Dureza
Derivados da Hipromelose
Mentol/administração & dosagem
Mentol/química
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Excipients); 0 (Tablets); 1490-04-6 (Menthol); 3NXW29V3WO (Hypromellose Derivatives)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.5186


  5 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441997
[Au] Autor:Bhunchu S; Muangnoi C; Rojsitthisak P; Rojsitthisak P
[Ti] Título:Curcumin diethyl disuccinate encapsulated in chitosan/alginate nanoparticles for improvement of its cytotoxicity against MDA-MB-231 human breast cancer cells.
[So] Source:Pharmazie;71(12):691-700, 2016 Dec 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Curcumin diethyl disuccinate (CDD) is a succinate prodrug of curcuminoids that has better stability in human plasma and improved in vitro cytotoxicity compared to curcumin. Therefore, CDD has the potential for further development as an anticancer agent. In this study, we focused on optimization of the formulation of CDD-loaded chitosan/alginate nanoparticles using Box-Behnken statistical design to enhance the therapeutic efficacy of CDD. Oil-in-water emulsification followed by ionotropic gelification was used to prepare the CDD-loaded chitosan/ alginate nanoparticles. A formulation with a 0.05:1 chitosan/alginate mass ratio, 0.65% (w/v) Pluronic F127 and 1.5 mg/ml CDD was found to be optimal. FTIR, TGA and XRD confirmed the encapsulation of CDD molecules in the nanoparticles. In vitro cytotoxicity and cellular uptake studies showed that CDD-loaded chitosan/alginate nanoparticles had significantly higher cytotoxicity and cellular uptake in human breast adenocarcinoma MDA-MB-231 cells, compared to free CDD. Physical and chemical stability studies indicated that the optimally formulated CDD-loaded chitosan/alginate nanoparticles were stable at 4 °C for 3 months.
[Mh] Termos MeSH primário: Alginatos/química
Antineoplásicos Fitogênicos/administração & dosagem
Antineoplásicos Fitogênicos/farmacologia
Neoplasias da Mama/tratamento farmacológico
Quitosana/química
Curcumina/análogos & derivados
Excipientes/química
Nanopartículas
Succinatos/administração & dosagem
Succinatos/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos Fitogênicos/farmacocinética
Neoplasias da Mama/metabolismo
Linhagem Celular Tumoral
Curcumina/administração & dosagem
Curcumina/farmacocinética
Curcumina/farmacologia
Composição de Medicamentos
Estabilidade de Medicamentos
Emulsões
Feminino
Seres Humanos
Poloxâmero
Pró-Fármacos
Succinatos/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Antineoplastic Agents, Phytogenic); 0 (Emulsions); 0 (Excipients); 0 (Prodrugs); 0 (Succinates); 0 (curcumin diethyl disuccinate); 106392-12-5 (Poloxamer); 9012-76-4 (Chitosan); IT942ZTH98 (Curcumin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6105


  6 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29301083
[Au] Autor:Yang Y; Cheng J; Garamus VM; Li N; Zou A
[Ti] Título:Preparation of an Environmentally Friendly Formulation of the Insecticide Nicotine Hydrochloride through Encapsulation in Chitosan/Tripolyphosphate Nanoparticles.
[So] Source:J Agric Food Chem;66(5):1067-1074, 2018 Feb 07.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Insecticide nicotine hydrochloride (NCT) was formulated as nanoparticles composed of chitosan (CS) and sodium tripolyphosphate (TPP) to undermine its adverse impacts on human health and reinforce its physicochemical stability. The study investigated the preparation and characterization of chitosan/tripolyphosphate nanoparticles (CS/TPP NPs) with good encapsulation efficiency (55%), uniform morphology, and physicochemical stability (45 days) through dynamic light scattering (DLS), transmission electron microscopy (TEM), and small-angle X-ray scattering (SAXS) measurements. A bioassay against Musca domestica NCT CS/TPP NPs exhibited good bioactivity and thermal stability. The effect of the monovalent salt (NaCl) on manipulating the formation and size distribution of ionically cross-linked nanoparticles was demonstrated as well. The formulation of NCT CS/TPP NPs could be a utility candidate in public health and agriculture.
[Mh] Termos MeSH primário: Quitosana
Química Verde
Inseticidas
Nanopartículas
Nicotina/análogos & derivados
Nicotina/química
Polifosfatos
[Mh] Termos MeSH secundário: Animais
Fenômenos Químicos
Composição de Medicamentos/métodos
Estabilidade de Medicamentos
Difusão Dinâmica da Luz
Moscas Domésticas
Microscopia Eletrônica de Transmissão
Difração de Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insecticides); 0 (Polyphosphates); 6M3C89ZY6R (Nicotine); 9012-76-4 (Chitosan); NU43IAG5BC (triphosphoric acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180105
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b04147


  7 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448291
[Au] Autor:Coca A; Agabiti-Rosei E; Cifkova R; Manolis AJ; Redón J; Mancia G
[Ad] Endereço:aHypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital Clínic (IDIBAPS), University of Barcelona, Barcelona, Spain bDepartment of Clinical and Experimental Sciences, University of Brescia cDepartment of Medicine, Azienda, Spedali Civili di Brescia, Brescia, Italy dCenter for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic eDepartment of Cardiology, Asklepeion General Hospital, Athens, Greece fINCLIVA, Research Institute, University of Valencia, CIBERObn ISCIII, Madrid, Spain gIRCCS, Istituto Auxologico Italiano hUniversity of Milano-Bicocca, Milano, Italy.
[Ti] Título:The polypill in cardiovascular prevention: evidence, limitations and perspective - position paper of the European Society of Hypertension.
[So] Source:J Hypertens;35(8):1546-1553, 2017 Aug.
[Is] ISSN:1473-5598
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:: Antihypertensive, lipid lowering, antidiabetic and antiplatelet treatments all substantially reduce the risk of cardiovascular morbid and fatal events. In real life, however, effective implementation of these treatments is rare, and thus their contribution to cardiovascular prevention is much less than it could be, based on research data. This article reviews the pros and cons of cardiovascular prevention by the polypill approach. It is argued that the high prevalence of individuals with a multifactorial risk profile provides a strong rationale for a therapeutic strategy based on the combination in a single tablet of drugs against different risk factors. It is further argued that other important favourable arguments exist. First, in real-life adherence to all above treatments is very low, leading to a major increase in the incidence and risk of cardiovascular outcomes. Second, although a large number of factors are involved, adherence is adversely affected by the complexity of the prescribed treatment regimen and can be considerably improved by treatment simplification. Third, recent studies in patients with a history of manifest cardiovascular disease have documented that different cardiovascular drugs can be combined in a single tablet with no loss of their individual efficacy or unexpected inconveniences and this does favour adherence to treatment and multiple risk factor control, supporting use of the polypill in secondary cardiovascular prevention. It is finally also mentioned, however, that the polypill may have some drawbacks and that at present no evidence is available that this approach reduces cardiovascular outcome to a greater degree than standard treatment strategies. Trials are under way to provide an answer to this question and thus allow the therapeutic value of this approach to be known.
[Mh] Termos MeSH primário: Anti-Hipertensivos/administração & dosagem
Doenças Cardiovasculares/prevenção & controle
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Hipoglicemiantes/administração & dosagem
Inibidores da Agregação de Plaquetas/administração & dosagem
[Mh] Termos MeSH secundário: Combinação de Medicamentos
Composição de Medicamentos
Europa (Continente)
Seres Humanos
Sociedades Médicas
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antihypertensive Agents); 0 (Drug Combinations); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Hypoglycemic Agents); 0 (Platelet Aggregation Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1097/HJH.0000000000001390


  8 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29384619
[Au] Autor:Zhao H; Wang YL; Peng JR; Zhang L; Qu Y; Chu BY; Dong ML; Tan LW; Qian ZY
[Ti] Título:Biodegradable Self-Assembled Micelles Based on MPEG-PTMC Copolymers: An Ideal Drug Delivery System for Vincristine.
[So] Source:J Biomed Nanotechnol;13(4):427-36, 2017 Apr.
[Is] ISSN:1550-7033
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite advantageous properties, micelles using methoxy poly(ethylene glycol)-poly(trimethylene carbonate) (MPEGPTMC) have not been widely studied. In this work, we aim to develop a novel vehicle for vincristine (VCR) based on a MPEG-PTMC micelle system. MPEG-PTMC with a series of molecular weights were synthesized and screened for the appropriate range for forming stable VCR micelles. The prepared micelles were then characterized in vitro and in vivo . VCR micelles presented high stability and ideal sustained release profile. The passive targeting effect was also enhanced compared with liposomal VCR. These results provide critical data to give the first clues regarding novel VCR micelles which exhibit potential for clinical application.
[Mh] Termos MeSH primário: Implantes Absorvíveis
Dioxanos/química
Implantes de Medicamento/química
Nanocápsulas/química
Polietilenoglicóis/química
Vincristina/administração & dosagem
Vincristina/química
[Mh] Termos MeSH secundário: Cristalização/métodos
Difusão
Composição de Medicamentos/métodos
Implantes de Medicamento/administração & dosagem
Micelas
Nanocápsulas/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dioxanes); 0 (Drug Implants); 0 (Micelles); 0 (Nanocapsules); 0 (monomethoxy poly(ethylene glycol)-block-poly(trimethylene carbonate)); 30IQX730WE (Polyethylene Glycols); 5J49Q6B70F (Vincristine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE


  9 / 17045 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29381027
[Au] Autor:Lee CW; Hu SC; Yen FL; Hsu LF; Lee IT; Lin ZC; Tsai MH; Huang CL; Liang CJ; Chiang YC
[Ti] Título:Magnolol Nanoparticles Exhibit Improved Water Solubility and Suppress TNF-α-Induced VCAM-1 Expression in Endothelial Cells.
[So] Source:J Biomed Nanotechnol;13(3):255-68, 2017 Mar.
[Is] ISSN:1550-7033
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The expression of the adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) on endothelial cells enables the attachment of leukocytes to the endothelium, which may lead to inflammation and the development of atherosclerosis. Magnolol is a major bioactive compound derived from the plant species Magnolia officinalis. In this study, we synthesized a novel nanoparticle formulation of magnolol to improve its water solubility and physicochemical properties, evaluated its effects on TNF-α-induced VCAM-1 expression in endothelial cells, and determined the signal transduction pathways involved. Our findings demonstrated that the magnolol nanoparticle system showed great improvements in physicochemical properties and water solubility owing to a reduction in particle size, transformation from a crystalline to amorphous structure, and the formation of hydrogen bonds with the nanoparticle carriers. In terms of its biological actions, magnolol nanoparticles attenuated TNF-α-induced VCAM-1 protein expression, promoter activity, and mRNA expression in endothelial cells in vitro. This was found to be mediated by the ERK, AKT, and NF-κB signaling pathways. In addition, magnolol nanoparticles inhibited TNF-α-induced leukocyte adhesion to endothelial cells, and suppressed TNF-α-induced VCAM-1 expression in the aortic endothelium of mice. In summary, since magnolol nanoparticles inhibit endothelial VCAM-1 expression and leukocyte adhesion to endothelial cells, this novel drug formulation may be a potentially useful therapeutic formulation to prevent the development of atherosclerosis and inflammatory diseases.
[Mh] Termos MeSH primário: Compostos de Bifenilo/administração & dosagem
Água Corporal/química
Células Endoteliais/efeitos dos fármacos
Células Endoteliais/metabolismo
Lignanas/administração & dosagem
Nanopartículas/administração & dosagem
Molécula 1 de Adesão de Célula Vascular/administração & dosagem
Molécula 1 de Adesão de Célula Vascular/metabolismo
[Mh] Termos MeSH secundário: Animais
Compostos de Bifenilo/química
Células Cultivadas
Regulação para Baixo/efeitos dos fármacos
Regulação para Baixo/fisiologia
Composição de Medicamentos/métodos
Seres Humanos
Lignanas/química
Camundongos
Camundongos Endogâmicos C57BL
Nanopartículas/química
Nanopartículas/ultraestrutura
Tamanho da Partícula
Solubilidade
Fator de Necrose Tumoral alfa
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biphenyl Compounds); 0 (Lignans); 0 (Tumor Necrosis Factor-alpha); 0 (Vascular Cell Adhesion Molecule-1); 001E35HGVF (magnolol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE


  10 / 17045 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29220341
[Au] Autor:Suvikas-Peltonen E; Palmgren J; Häggman V; Celikkayalar E; Manninen R; Airaksinen M
[Ad] Endereço:Pharmacy Department, Central Hospital of Satakunta, Pori, Finland.
[Ti] Título:Auditing Safety of Compounding and Reconstituting of Intravenous Medicines on Hospital Wards in Finland.
[So] Source:Int J Pharm Compd;21(6):518-529, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:On the hospital wards in Finland, nurses generally reconstitute intravenous medicines, such as antibiotics, analgesics, and antiemetics prescribed by doctors. Medicine reconstitution is prone to many errors. Therefore, it is important to identify incorrect practices in the reconstitution of medicine to improve patient safety in hospitals. The aim of this study was to audit the compounding and reconstituting of intravenous medicines on hospital wards in a secondary-care hospital in Finland by using an assessment tool and microbiological testing for identifying issues posing patient safety risks. A hospital pharmacist conducted an external audit by using a validated 65-item assessment tool for safe-medicine compounding practices on 20 wards of the selected hospital. Also, three different microbiological samples were collected to assure the aseptics. Practices were evaluated using a four-point rating scale of "never performed," "rarely performed," "often performed," and "always performed," and were based on observation and interviews with nurses or ward pharmacists. In addition, glove-, settle plate-, and media fill-tests were collected. Associations between microbial sample results and audit-tool results were discussed. Altogether, only six out of the 65 items were fully implemented in all wards; these were related to logistic practices and quality assurance. More than half of the wards used incorrect practices ("rarely performed" or "never performed") for five items. Most of these obviated practices related to aseptic practices. All media-fill tests were clean but the number of colony forming units in glove samples and settle- plate samples varied from 0 to >100. More contamination was found in wards where environmental conditions were inadequate or the use of gloves was incorrect. Compounding practices were [mostly] quite well adapted, but the aseptic practices needed improvement. Attention should have been directed particularly to good aseptic techniques and compounding environment on the wards. These results can be used for updating the guidelines and for training nurses involved in compounding.
[Mh] Termos MeSH primário: Composição de Medicamentos/normas
Segurança do Paciente
Serviço de Farmácia Hospitalar/normas
[Mh] Termos MeSH secundário: Administração Intravenosa
Guias como Assunto
Esterilização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE



página 1 de 1705 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde